Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Clinicopathological Significance of Long Non-Coding RNA GHET1 in Human Cancers: A Meta-Analysis

Author(s): Arash Poursheikhani, Negin Nokhandani, Hassan Yousefi, Dorsa M. Rad and Amirhossein Sahebkar*

Volume 21, Issue 14, 2020

Page: [1422 - 1432] Pages: 11

DOI: 10.2174/1389201021999200727163238

Price: $65

Abstract

Background: Cancer is considered as the main public health problem and the second leading cause of morbidity and mortality worldwide. Numerous environmental-lifestyle related risk factors account for around one-third of cancer deaths. Recently, the key role of lncRNAs has been widely investigated in a variety of disorders, including cancer. The lncRNA GHET1 has been considered as an essential oncogenic lncRNA in many types of human cancers. Clinical investigations indicated that expression of lncRNA GHET1 is correlated with clinicopathological characteristics in cancer. This metaanalysis investigated the correlation between the lncRNA GHET1 expression and clinicopathological features in different types of cancers.

Materials and Methods: Comprehensive literature searches in PubMed, Scopus, and Web of Knowledge were conducted up to April 11, 2019. Sixteen studies were included in this meta-analysis. All statistical analyses were conducted using Stata software, version 12.0.

Results: The pooled OR and 95%CIs of the sixteen relevant studies showed that over expression of lncRNA GHET1 was associated with tumor-size ≥5 cm (OR= 2.51, 95% CI: 1.89-3.33, p=0.00, I2=38.30%), positive lymph node metastasis (OR= 2.83, 95% CI: 1.78-4.52, p=0.00, I2=45.60%), advanced tumor stage (OR= 3.92, 95% CI: 2.97-5.19, p=0.00, I2=0.00%), positive distant metastasis (OR= 5.74, 95% CI: 2.58-12.77, p=0.00, I2=0.00%), advanced tumor status (OR= 2.97, 95% CI: 1.40- 6.29, p=0.01, I2=34.70%), and positive vascular invasion (OR= 2.69, 95% CI: 1.61-4.50, p=0.00, I2=29.20%).

Conclusion: Taken together, the current study demonstrated that overexpression of lncRNA GHET1 is significantly associated with clinicopathological features in human cancers. Our results suggested that lncRNA GHET1 can be utilized as a prognostic biomarker in human cancer.

Keywords: Clinicopathological features, lncRNA, GHET1, cancer, meta-analysis, vascular invasion.

« Previous Next »
Graphical Abstract

[1]
Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer, 2010, 127(12), 2893-2917.
[http://dx.doi.org/10.1002/ijc.25516] [PMID: 21351269]
[2]
Yang, C.; Li, Z.; Li, Y.; Xu, R.; Wang, Y.; Tian, Y.; Chen, W. Long non-coding RNA NEAT1 overexpression is associated with poor prognosis in cancer patients: A systematic review and meta-analysis. Oncotarget, 2017, 8(2), 2672-2680.
[http://dx.doi.org/10.18632/oncotarget.13737] [PMID: 27926523]
[3]
Fan, Y-H.; Fang, H.; Ji, C.X.; Xie, H.; Xiao, B.; Zhu, X-G. Long noncoding RNA CCAT2 can predict metastasis and poor prognosis: A meta-analysis. Clin. Chim. Acta, 2017, 466, 120-126.
[http://dx.doi.org/10.1016/j.cca.2017.01.016] [PMID: 28089750]
[4]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin., 2015, 65(1), 5-29.
[http://dx.doi.org/10.3322/caac.21254] [PMID: 25559415]
[5]
Forouzanfar, M.H.; Afshin, A.; Alexander, L.T.; Anderson, H.R.; Bhutta, Z.A.; Biryukov, S.; Brauer, M.; Burnett, R.; Cercy, K.; Charlson, F.J. GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet, 2016, 388(10053), 1659-1724.
[http://dx.doi.org/10.1016/S0140-6736(16)31679-8] [PMID: 27733284]
[6]
McGuire, S. World cancer report 2014. Geneva, Switzerland: World Health Organization, international agency for research on cancer. Adv. Nutr.: Int. Rev. J. , 2015; 7, pp. (2)418-419.
[7]
Lu, D.; Luo, P.; Wang, Q.; Ye, Y.; Wang, B. lncRNA PVT1 in cancer: A review and meta-analysis. Clin. Chim. Acta, 2017, 474, 1-7.
[http://dx.doi.org/10.1016/j.cca.2017.08.038] [PMID: 28866116]
[8]
Yang, J.; Li, J.; Liu, B.; Zhang, R.; Gu, F.; Zhao, J.; Cheng, S. Long noncoding RNA AK021443 promotes cell proliferation and migration by regulating epithelial-mesenchymal transition in hepatocellular carcinoma cells. DNA Cell Biol., 2018, 37(5), 481-490.
[http://dx.doi.org/10.1089/dna.2017.4030] [PMID: 29638164]
[9]
Kong, X.P.; Yao, J.; Luo, W.; Feng, F.K.; Ma, J.T.; Ren, Y.P.; Wang, D.L.; Bu, R.F. The expression and functional role of a FOXC1 related mRNA-lncRNA pair in oral squamous cell carcinoma. Mol. Cell. Biochem., 2014, 394(1-2), 177-186.
[http://dx.doi.org/10.1007/s11010-014-2093-4] [PMID: 24889262]
[10]
Hu, G.; Yang, T.; Zheng, J.; Dai, J.; Nan, A.; Lai, Y.; Zhang, Y.; Yang, C.; Jiang, Y. Functional role and mechanism of lncRNA LOC728228 in malignant 16HBE cells transformed by anti-benzopyrene-trans-7,8-dihydrodiol-9,10-epoxide. Mol. Carcinog., 2015, 54(Suppl. 1), E192-E204.
[http://dx.doi.org/10.1002/mc.22314] [PMID: 25820656]
[11]
Abdeahad, H.; Avan, A.; Pashirzad, M.; Khazaei, M.; Soleimanpour, S.; Ferns, G.A.; Fiuji, H.; Ryzhikov, M.; Bahrami, A.; Hassanian, S.M. The prognostic potential of long noncoding RNA HOTAIR expression in human digestive system carcinomas: A meta-analysis. J. Cell. Physiol., 2019, 234(7), 10926-10933.
[http://dx.doi.org/10.1002/jcp.27918] [PMID: 30569489]
[12]
Bartonicek, N.; Maag, J.L.; Dinger, M.E. Long noncoding RNAs in cancer: Mechanisms of action and technological advancements. Mol. Cancer, 2016, 15(1), 43.
[http://dx.doi.org/10.1186/s12943-016-0530-6] [PMID: 27233618]
[13]
Zhang, F.; Zhang, L.; Zhang, C. Long noncoding RNAs and tumorigenesis: genetic associations, molecular mechanisms, and therapeutic strategies. Tumour Biol., 2016, 37(1), 163-175.
[http://dx.doi.org/10.1007/s13277-015-4445-4] [PMID: 26586396]
[14]
Brosnan, C.A.; Voinnet, O. The long and the short of noncoding RNAs. Curr. Opin. Cell Biol., 2009, 21(3), 416-425.
[http://dx.doi.org/10.1016/j.ceb.2009.04.001] [PMID: 19447594]
[15]
Gupta, R.A.; Shah, N.; Wang, K.C.; Kim, J.; Horlings, H.M.; Wong, D.J.; Tsai, M-C.; Hung, T.; Argani, P.; Rinn, J.L.; Wang, Y.; Brzoska, P.; Kong, B.; Li, R.; West, R.B.; van de Vijver, M.J.; Sukumar, S.; Chang, H.Y. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature, 2010, 464(7291), 1071-1076.
[http://dx.doi.org/10.1038/nature08975] [PMID: 20393566]
[16]
Yang, F.; Bi, J.; Xue, X.; Zheng, L.; Zhi, K.; Hua, J.; Fang, G. Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J., 2012, 279(17), 3159-3165.
[http://dx.doi.org/10.1111/j.1742-4658.2012.08694.x] [PMID: 22776265]
[17]
Song, W.; Zou, S.B. Prognostic role of lncRNA HOTAIR in esophageal squamous cell carcinoma. Clin. Chim. Acta, 2016, 463, 169-173.
[http://dx.doi.org/10.1016/j.cca.2016.10.035] [PMID: 27810266]
[18]
Poursheikhani, A.; Bahmanpour, Z.; Razmara, E.; Mashouri, L.; Taheri, M.; Morshedi Rad, D.; Yousefi, H.; Bitaraf, A.; Babashah, S. Non-coding RNAs underlying chemoresistance in gastric cancer. Cell. Oncol., 2020.
[http://dx.doi.org/10.1007/s13402-020-00528-2]
[19]
Li, J.; Xie, J.; Liao, Z.; Yu, Y.; Chen, Z. High expression of long non-coding RNA GHET1 is associated with unfavorable prognosis in hepatocellular carcinoma. Int. J. Clin. Exp. Med., 2017, 10(2), 2374-2385.
[20]
Liu, H.; Wu, Y. Long non-coding RNA gastric carcinoma highly expressed transcript 1 promotes cell proliferation and invasion in human head and neck cancer. Oncol. Lett., 2018, 15(5), 6941-6946.
[http://dx.doi.org/10.3892/ol.2018.8185] [PMID: 29725422]
[21]
Jin, L.; He, Y.; Tang, S.; Huang, S. LncRNA GHET1 predicts poor prognosis in hepatocellular carcinoma and promotes cell proliferation by silencing KLF2. J. Cell. Physiol., 2018, 233(6), 4726-4734.
[http://dx.doi.org/10.1002/jcp.26257] [PMID: 29139562]
[22]
Guan, Z.B.; Cao, Y.S.; Li, Y.; Tong, W.N.; Zhuo, A.S. Knockdown of lncRNA GHET1 suppresses cell proliferation, invasion and LATS1/YAP pathway in non small cell lung cancer. Cancer Biomark., 2018, 21(3), 557-563.
[http://dx.doi.org/10.3233/CBM-170431] [PMID: 29286919]
[23]
Yang, W.; Shan, Z.; Zhou, X.; Peng, L.; Zhi, C.; Chai, J.; Liu, H.; Yang, J.; Zhang, Z. Knockdown of lncRNA GHET1 inhibits osteosarcoma cells proliferation, invasion, migration and EMT in vitro and in vivo. Cancer Biomark., 2018, 23(4), 589-601.
[http://dx.doi.org/10.3233/CBM-181863] [PMID: 30475755]
[24]
Shen, Q.M.; Wang, H.Y.; Xu, S. LncRNA GHET1 predicts a poor prognosis of the patients with non-small cell lung cancer. Eur. Rev. Med. Pharmacol. Sci., 2018, 22(8), 2328-2333.
[PMID: 29762836]
[25]
Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol., 2010, 25(9), 603-605.
[http://dx.doi.org/10.1007/s10654-010-9491-z] [PMID: 20652370]
[26]
Tao, R.; Hu, S.; Wang, S.; Zhou, X.; Zhang, Q.; Wang, C.; Zhao, X.; Zhou, W.; Zhang, S.; Li, C.; Zhao, H.; He, Y.; Zhu, S.; Xu, J.; Jiang, Y.; Li, L.; Gao, Y. Association between indel polymorphism in the promoter region of lncRNA GAS5 and the risk of hepatocellular carcinoma. Carcinogenesis, 2015, 36(10), 1136-1143.
[http://dx.doi.org/10.1093/carcin/bgv099] [PMID: 26163879]
[27]
Kong, H.; Wu, Y.; Zhu, M.; Zhai, C.; Qian, J.; Gao, X.; Wang, S.; Hou, Y.; Lu, S.; Zhu, H. Long non-coding RNAs: Novel prognostic biomarkers for liver metastases in patients with early stage colorectal cancer. Oncotarget, 2016, 7(31), 50428-50436.
[http://dx.doi.org/10.18632/oncotarget.10416] [PMID: 27391432]
[28]
Yan, H.; Zhang, D-Y.; Li, X.; Yuan, X-Q.; Yang, Y-L.; Zhu, K-W.; Zeng, H.; Li, X-L.; Cao, S.; Zhou, H-H.; Zhang, W.; Chen, X.P. Long non-coding RNA GAS5 polymorphism predicts a poor prognosis of acute myeloid leukemia in Chinese patients via affecting hematopoietic reconstitution. Leuk. Lymphoma, 2017, 58(8), 1948-1957.
[http://dx.doi.org/10.1080/10428194.2016.1266626] [PMID: 27951730]
[29]
Sun, W.; Yang, Y.; Xu, C.; Xie, Y.; Guo, J. Roles of long noncoding RNAs in gastric cancer and their clinical applications. J. Cancer Res. Clin. Oncol., 2016, 142(11), 2231-2237.
[http://dx.doi.org/10.1007/s00432-016-2183-7] [PMID: 27246953]
[30]
Zhu, Y.; Tong, Y.; Wu, J.; Liu, Y.; Zhao, M. Knockdown of LncRNA GHET1 suppresses prostate cancer cell proliferation by inhibiting HIF-1alpha/Notch-1 signaling pathway via KLF2. Biofactors, 2019, 45(3), 364-373.
[31]
Zhou, H.Y.; Zhu, H.; Wu, X.Y.; Chen, X.D.; Qiao, Z.G.; Ling, X.; Yao, X.M.; Tang, J.H. Expression and clinical significance of long-non-coding RNA GHET1 in pancreatic cancer. Eur. Rev. Med. Pharmacol. Sci., 2017, 21(22), 5081-5088.
[PMID: 29228419]
[32]
Zhang, Q.; Zhang, Y.; Wang, Y. GHET1 acts as a prognostic indicator and functions as an oncogenic lncRNA in cervical cancer. Biosci. Rep., 2019, 39(4)BSR20182506
[http://dx.doi.org/10.1042/BSR20182506] [PMID: 30948501]
[33]
Li, J.; Jiang, X.; Li, Z.; Huang, L.; Zhou, Y.; Liu, Y.; Cui, Y. Long noncoding RNA GHET1 in human cancer. Clin. Chim. Acta, 2019, 488, 111-115.
[http://dx.doi.org/10.1016/j.cca.2018.11.007] [PMID: 30399371]
[34]
Xie, W.; Liu, X.; Chen, Q.; Ma, M.; Yang, X.; Gong, B.; Sun, T.; Chen, J. Silencing of the long non-coding RNA GHET1 inhibits cell proliferation and migration of renal cell carcinoma through epithelial-mesenchymal transition. Oncol. Lett., 2019, 17(3), 3173-3180.
[PMID: 30867747]
[35]
Li, P.; Zhong, X.; Li, J.; Liu, H.; Ma, X.; He, R.; Zhao, Y. MicroRNA-30c-5p inhibits NLRP3 inflammasome-mediated endothelial cell pyroptosis through FOXO3 down-regulation in atherosclerosis. Biochem. Biophys. Res. Commun., 2018, 503(4), 2833-2840.
[http://dx.doi.org/10.1016/j.bbrc.2018.08.049] [PMID: 30119891]
[36]
Song, R.; Zhang, J.; Huang, J.; Hai, T. Long non-coding RNA GHET1 promotes human breast cancer cell proliferation, invasion and migration via affecting epithelial mesenchymal transition. Cancer Biomark., 2018, 22(3), 565-573.
[http://dx.doi.org/10.3233/CBM-181250] [PMID: 29843220]
[37]
Sarrafzadeh, S.; Taheri, M.; Geranpayeh, L.; Ghafouri-Fard, S.; Ghafouri-Fard, S. Long non-coding RNA GHET1 Is Possibly Involved in the Pathogenesis of a Fraction of Breast Cancers. Int. J. Cancer Managem., 2017, 10(10)e9920
[http://dx.doi.org/10.5812/ijcm.9920]
[38]
Liu, H.; Zhen, Q.; Fan, Y. LncRNA GHET1 promotes esophageal squamous cell carcinoma cells proliferation and invasion via induction of EMT. Int. J. Biol. Markers, 2017, 32(4), e403-e408.
[http://dx.doi.org/10.5301/ijbm.5000304] [PMID: 28983895]
[39]
Esfandi, F.; Taheri, M. Long noncoding RNAs expression in gastric cancer. J. Cell. Biochem., 2019, 120(8), 13802-13809.
[http://dx.doi.org/10.1002/jcb.28653]
[40]
Yang, F.; Xue, X.; Zheng, L.; Bi, J.; Zhou, Y.; Zhi, K.; Gu, Y.; Fang, G. Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability. FEBS J., 2014, 281(3), 802-813.
[http://dx.doi.org/10.1111/febs.12625] [PMID: 24397586]
[41]
Dang, C.V.; Le, A.; Gao, P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res 2009, 15(21), 6479-6483.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-0889] [PMID: 19861459]
[42]
Han, M.; Wang, Y.; Gu, Y.; Ge, X.; Seng, J.; Guo, G.; Zhang, X.; Zhao, Y.; Dou, D. lncRNA GHET1 knockdown suppresses breast cancer activity in vitro and in vivo. Am. J. Transl. Res., 2019, 11(1), 31-44.
[PMID: 30787968]
[43]
Cao, W.; Liu, B.; Ma, H. Long non-coding RNA GHET1 promotes viability, migration and invasion of glioma cell line U251 by down-regulation of miR-216a. Eur. Rev. Med. Pharmacol. Sci., 2019, 23(4), 1591-1599.
[PMID: 30840282]
[44]
Ni, W.; Luo, L.; Zuo, P.; Li, R.P.; Xu, X.B.; Wen, F.; Hu, D. lncRNA GHET1 down-regulation suppresses the cell activities of glioma. Cancer Biomark., 2018, 23(1), 9-22.
[http://dx.doi.org/10.3233/CBM-171002] [PMID: 30103301]
[45]
Zhang, X.; Bo, P.; Liu, L.; Zhang, X.; Li, J. Overexpression of long non-coding RNA GHET1 promotes the development of multidrug resistance in gastric cancer cells. Biomed. Pharmacother., 2017, 92, 580-585.
[http://dx.doi.org/10.1016/j.biopha.2017.04.111] [PMID: 28578256]
[46]
Ding, G.; Li, W.; Liu, J.; Zeng, Y.; Mao, C.; Kang, Y.; Shang, J. LncRNA GHET1 activated by H3K27 acetylation promotes cell tumorigenesis through regulating ATF1 in hepatocellular carcinoma. Biomed. Pharmacother., 2017, 94, 326-331.
[http://dx.doi.org/10.1016/j.biopha.2017.07.046]
[47]
Zhou, J.; Li, X.; Wu, M.; Lin, C.; Guo, Y.; Tian, B. Knockdown of long noncoding RNA GHET1 inhibits cell proliferation and invasion of colorectal cancer. Oncol. Res., 2016, 23(6), 303-309.
[http://dx.doi.org/10.3727/096504016X14567549091305]
[48]
Huang, H.; Liao, W.; Zhu, X.; Liu, H.; Cai, L. Knockdown of long noncoding RNA GHET1 inhibits cell activation of gastric cancer. Biomed. Pharmacother., 2017, 92, 562-568.
[http://dx.doi.org/10.1016/j.biopha.2017.05.088]

Rights & Permissions Print Cite
Article Metrics
33
© 2024 Bentham Science Publishers | Privacy Policy